The post SOL’s 30% Open Interest Drop Puts $68 Back In Focus appeared on BitcoinEthereumNews.com. Solana (SOL) futures dropped sharply in May as traders reducedThe post SOL’s 30% Open Interest Drop Puts $68 Back In Focus appeared on BitcoinEthereumNews.com. Solana (SOL) futures dropped sharply in May as traders reduced

SOL’s 30% Open Interest Drop Puts $68 Back In Focus

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Solana (SOL) futures dropped sharply in May as traders reduced leveraged exposure across all exchanges. SOL open interest (OI) dropped to $1.90 billion on Thursday from $2.75 billion on May 11, a 30% decline, while funding rates remained close to neutral. The combination points to weakening investor sentiment as SOL eyes a retest of its yearly low at $68. 

SOL spot demand offsets futures market weakness

The aggregated funding rate for Solana futures held near -0.005, showing balanced positioning between longs and shorts. SOL traders have not built aggressive directional bets despite the recent price slide to $80.

SOL price, aggregated open interest, and funding rate. Source: velo chart

At the same time, the aggregated futures volume cumulative volume delta (CVD) for stablecoin-margined orders fell to a yearly low of -$13 billion. The CVD tracks whether buyers or sellers are more active over time. The decline signals stronger sell-side pressure in futures markets through May.

BTC price, aggregated spot and futures CVD. Source: Coinalyze 

However, spot activity paints a steadier picture. Spot CVD has improved to $350 million since March, showing that buyers have continued to absorb supply on spot exchanges even as derivatives positioning has weakened. 

The positive flows into spot SOL exchange-traded funds (ETFs) added to that trend. The monthly net inflows reached $113 million in May, marking the strongest monthly total for SOL ETFs in 2026.

The split between futures selling and steady spot accumulation often points to a lower level of speculative appetite rather than panic selling. This indicates that leveraged traders reduced risk exposure, while spot buyers continued to add positions gradually.

Related: Three key XRP metrics suggest ‘explosive price expansion’ is next

SOL retests the $80 price floor of a three-month range

From a technical standpoint, SOL continues to trade inside a broad range between $80 and $95. The range formed after Solana fell 42% during Q1. The price returned to the lower boundary on Wednesday after another rejection near the resistance level.

SOL/USD, one-day chart. Source: Cointelegraph/TradingView

A move below $80 places focus on the yearly low near $68. The liquidation heat maps show more than $800 million in cumulative long leverage sitting near that zone, making it an important liquidity pocket if downside pressure increases.

Crypto trader Cold Blooded Shiller described SOL as one of the weaker large-cap charts in the market. In a post on X, the trader said SOL has been in a downtrend since October and lacks strong support below the current price level of $80.

Crypto commentator Zoe also placed bids near $67, closely aligning with the yearly low and the largest cluster of leveraged liquidations identified on the open leveraged positions heatmap. 

SOL liquidation map. Source: CoinGlass

Related: HYPE chases new highs as ETF inflows, institutional adoption accelerate

Source: https://cointelegraph.com/markets/solana-open-interest-drops-30-as-68-retest-comes-back-into-play?utm_source=rss_feed&utm_medium=feed&utm_campaign=rss_partner_inbound

Market Opportunity
Solana Logo
Solana Price(SOL)
$81.12
$81.12$81.12
-0.94%
USD
Solana (SOL) Live Price Chart

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Share
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Share
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage